Incretin-based therapies after bariatric surgery are associated with clinically meaningful augmented weight loss, according to a recent cohort study published in eClinicalMedicine. This trend, paired with the development of new oral small-molecule GLP-1 agents like Corxel Pharmaceuticals’ CX11, marks a shift toward combining surgical and pharmacological interventions to manage obesity. While these therapies expand treatment options, challenges remain regarding patient access, drug supply, and the effectiveness of preventative screening guidelines.
How are weight loss treatments evolving post-surgery?
Patients who undergo bariatric surgery are now frequently prescribed incretin-based therapies to improve weight loss results. Data suggests these outcomes are both dose- and timing-dependent. Alongside this, the pharmaceutical pipeline is moving toward oral delivery systems. Corxel Pharmaceuticals reported that its investigational oral small-molecule GLP-1 agent, CX11, resulted in 11.5% weight loss by week 36 in a phase II trial for individuals with overweight or obesity. Similarly, the investigational drug bofanglutide reduced HbA1c levels at 24 weeks in a phase IIb trial of Chinese adults with type 2 diabetes, as reported in the Annals of Internal Medicine, though gastrointestinal events were common.
Long-term resistance training was associated with a substantially lower risk of type 2 diabetes in a study of over 140,000 healthcare professionals published in JAMA Network Open.
What are the current hurdles for diabetes and obesity management?
Despite advancements in drug development, systemic barriers to effective care persist. A randomized trial published in the Annals of Internal Medicine found that a nurse-delivered telehealth program did not substantially lower HbA1c in diabetes patients compared to a self-monitoring control program. Furthermore, national data published in JAMA Pediatrics indicated that adapted American Diabetes Association youth screening guidelines showed a poor ability to predict prediabetes or early-onset type 2 diabetes before age 45.
Supply chain issues are also complicating patient access. Reuters reported that the supply of oral progesterone appears to be shrinking, with patients, clinicians, and pharmacists reporting recent intermittent shortages. Meanwhile, legislative efforts to reduce costs are underway; Axios reports that a bipartisan Senate proposal to cap insulin costs at $35 per month for privately insured patients has gained momentum.
How is the regulatory landscape for metabolic health changing?
Federal agencies are currently reevaluating safety standards for hormonal treatments. HHS has proposed easing safety warnings on testosterone labeling, including eliminating a limitation on use for age-related low testosterone and removing certain prostate cancer-related warnings. These changes follow a broader trend of shifting guidelines for metabolic and endocrine health. For instance, a systematic review and meta-analysis in the Journal of Clinical Endocrinology & Metabolism found that women with a history of idiopathic premature adrenarche face an increased risk of long-term insulin resistance and hyperandrogenism.
Preventative strategies are also under scrutiny. A microsimulation modeling study in Lancet Regional Health Americas suggested that vitamin D supplementation for adults with prediabetes could reduce the lifetime cumulative incidence of diabetes by 8%, with a net monetary benefit of $15,483.
How are obesity drugs reaching patients?
Access to weight loss medication remains uneven. While many older adults are unaware that they’re about to gain access to obesity drugs through a Medicare pilot program, according to CNBC, other high-profile cases have raised questions about how drugs are distributed. STAT examined why the investigational obesity drug retatrutide might be prescribed for pulmonary hypertension as questions swirled over the mystery patient who gained access through an expanded-use program.
Tragic outcomes highlight the severity of untreated conditions. In Michigan, a couple was charged with murder after their 7-year-old son, who weighed 255 pounds, died of dilated cardiomyopathy, as reported by the Associated Press.
Frequently Asked Questions
- Can bariatric surgery patients take GLP-1 drugs? Yes, data in eClinicalMedicine shows that incretin-based therapies after bariatric surgery were associated with clinically meaningful augmented weight loss in a dose- and timing-dependent manner.
- Are there new oral weight loss drugs in development? Yes, Corxel Pharmaceuticals is testing CX11, an oral small-molecule GLP-1 agent that yielded 11.5% weight loss by week 36 in a phase II trial.
- Does telehealth help manage HbA1c levels? According to a trial in the Annals of Internal Medicine, a nurse-delivered telehealth program did not substantially lower HbA1c in diabetes patients compared with a self-monitoring control program.
- Is there a cap on insulin costs? A bipartisan Senate proposal currently seeks to cap monthly insulin costs at $35 for privately insured patients.
Stay informed on the latest medical research and policy changes by subscribing to our health newsletter. Have questions about these findings? Share your thoughts in the comments below.
